Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
NCT07277270Phase 1Recruiting
- Sponsor
- GSK
- Start
- Dec 2025
- Primary completion
- Feb 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 6
01
Overview
Phase 1 trial of risvutatug rezetecan in colorectal cancer (CRC) and prostate cancer (PCa) (3 cohorts), sponsored by GSK. Primary endpoints: Adverse Events at 31 weeks, Adverse Events by severity at 31 weeks and 2 more. Started Dec 2025; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
colorectal cancer (CRC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07277270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07277270.